focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Expect this sleeping giant to awake within weeks
Ondine certainly seems to be in a sweet spot as it exploits concerns surrounding increased antibiotic resistance. Results of Steriwave look compelling commercially and fundamentally. Word of mouth is spreading in the health arena quickly and York is currently evaluating for NHS rollout. Could be a sleeping giant if things go well.
Ondine Biomedical Inc - Vancouver-based life sciences company - Announces significant commercial progress to date in 2024, ahead of management's expectations. Says Ondine's Steriwave technology is deploying in eight new healthcare facilities, including six new hospitals. This brings the total number of hospitals to 22, representing a 38% increase year-to-date and nearly quadruple the number a year ago. Two orthopedic surgeon group practices in the Toronto area will also shortly begin offering Steriwave to patients undergoing elective orthopedic procedures.
See
Https://ondinebio.com/wp-content/uploads/2023/10/OBI_Financial-Statements-06.30.2023-FINAL.pdf
Https://ondinebio.com/wp-content/uploads/2023/05/Ondine-Biomedical-2022-Annual-Report.pdf
On 01/08/23, Ondine issued an RNS stating
"Ondine commences first NHS Steriwave® pilot
Mid Yorkshire Teaching NHS Trust will be using Ondine's nasal photodisinfection therapy prior to orthopaedic surgeries at Pontefract Hospital over a six-month pilot"
Does anyone know if this was undertaken and, if so, when the results are likely to be published?
The painless, five-minute treatment prevents the spread of the pathogens, including superbugs, without contributing to the growing problem of antimicrobial resistance.
Ondine said the YHEC, known for its expertise in health economics evaluations, would lead the economic analysis alongside an ongoing Steriwave pilot study at the Mid Yorkshire Teaching NHS Trust.
The pilot involved 500 patients undergoing elective hip and knee surgeries over a six-month period, with the analysis aiming to supplement the pilot's findings and further support the wider adoption of Steriwave across the NHS.
Ondine said Steriwave had already gained traction in major Canadian hospitals including the Vancouver General Hospital, the Ottawa Hospital, and the Mazankowski Alberta Heart Institute.
A recent study by VGH, published in the Canadian Journal of Surgery, demonstrated a 66.5% reduction in post-surgical infection rates following the use of Steriwave in spine surgery patients.
The study also highlighted significant cost savings of $2.5m annually.
Ondine said to date there had been no reports of serious adverse events associated with Steriwave treatment.
Ondine Biomedical announced on Tuesday that it is joining forces with the Mid Yorkshire Teaching NHS Trust, Health Innovation Yorkshire and Humber, and the York Health Economics Consortium (YHEC) to assess the potential cost savings associated with using its 'Steriwave' technology.
The AIM-traded firm said the focus of the evaluation was on reducing the incidence of surgical site infections (SSIs), a major healthcare challenge within the NHS.
SSIs represent a significant strain on the NHS, afflicting one in every 20 surgical patients.
The infections can cause individual costs of up to £0.1m per patient, with the overall economic burden on NHS England exceeding £2bn annually.
Rising antimicrobial resistance (AMR) was threatening to further escalate the costs as standard antibiotic treatments, like mupirocin, became less effective.
Ondine said Steriwave offered a promising alternative approach, using a photosensitizer that, when activated by a specific wavelength of red light, eliminates harmful pathogens within the nose - a known reservoir for infection-causing bacteria like Staphylococcus aureus and MRSA.
The painless, five-minute treatment prevents the spread of the pathogens, including superbugs, without contributing to the growing problem of antimicrobial resistance.
Steriwave is also being used in major hospitals across Canada, including Vancouver General Hospital (VGH), The Ottawa Hospital (TOH), and the Mazankowski Alberta Heart Institute
Yet their revenues are minuscule
Current SP
9.22-9.4p
Much lower
so have added to my holding
Ondine Biomedical Inc. (LON:OBI), Mid Yorkshire Teaching NHS Trust, and Health Innovation Yorkshire and Humber are partnering with the York Health Economics Consortium (YHEC) to evaluate the use of Ondine's light-activated antimicrobial, Steriwave®, to reduce the incidence of surgical site infections (SSIs).
SSIs are one of the most common healthcare-associated infections (HAIs) and affect one in every 20 patients who undergo a surgical procedure in the NHS. SSIs can cost up to £100,000 per patient, and the overall cost of HAIs to NHS England is over £2 billion a year. These costs are expected to rise as growing rates of antimicrobial resistance (AMR) make the current standard of care - the antibiotic mupirocin - less effective.
Steriwave uses a proprietary photosensitizer, which is activated by a specific wavelength of red light, to eliminate infection-causing pathogens in the nose. The nose is a reservoir for pathogens like Staphylococcus aureus and MRSA which are known to cause SSIs. Steriwave eliminates these pathogens, including superbugs, in a painless five-minute treatment and prevents them from spreading and causing infections. Importantly, unlike today's antibiotics, the use of Steriwave does not trigger antimicrobial resistance.
The health economic analysis is being undertaken by YHEC, an internationally renowned provider of health economics evaluations, and will supplement the ongoing Steriwave pilot at Mid Yorkshire Teaching NHS Trust, which involves 500 elective hip and knee surgery patients over a period of six months. The findings will be used to support adoption of Steriwave across the NHS.
Dr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust, commented: "We are very pleased to be partnering with Ondine and the YHEC on this economic analysis to support the promising results of the Steriwave pilot we have seen so far. The data from the health economic analysis will support the results of our pilot, and we hope to be able to share these later this year."
Good news
to hopefully get to SP moving higher
Wait for 9p or lower
9.1565-9.69p
Canadian life sciences company, Ondine Biomedical Inc., (AIM: OBI) announces that on 25 January 2024 ("Grant Date") it awarded a total of 11,950,000 stock options ("Options") to subscribe for new common shares in the Company. This strategic move aligns with the Company's Option Plan, emphasizing the commitment to attracting, retaining, and inspiring key talent within its workforce, including employees, directors, advisory board members, and key consultants.
In the period since 30 June 2023, 4,355,000 options have naturally expired or been forfeited. Following the above grant of Options, Ondine Biomedical now has a total of 15,640,000 outstanding Options in issue, equivalent to 6.9% of the Company's current issued share capital.
9.51-9.875p
Good time to BUY before next news
imho - dyor
Ondine Biomedical Inc on Wednesday said that the research it presented at a conference in San Francisco proves the efficacy of its Steriwave nasal photo disinfection system.
According to the Vancouver-based life sciences company, the system significantly reduces pathogens in the nose but does not produce long-term adverse effects on the nasal microbiome.
The research, which was presented at the SPIE Photonics West conference in San Francisco, demonstrated an immediate and highly significant reduction in viable bacterial cells and number of species, sustained for at least 24 hours.
"These findings support Steriwave as an efficient, potent, short-acting, and non-selective method of nasal decolonization, with the advantage of rapid recovery of the native microbiome post-treatment," Ondine commented.
Ondine Biomedical shares were trading 1.3% lower at 10.11 pence each in London on Wednesday afternoon.
By Holly Beveridge, Alliance News reporter
Research presented by Canadian life sciences company, Ondine Biomedical Inc. (LON:OBI), at the prestigious SPIE Photonics West conference in San Francisco, California shows that treatment with its Steriwave® Nasal Photodisinfection System significantly reduces pathogens in the nose - a reservoir for bacteria - yet does not produce long-term adverse effects on the nasal microbiome.[*]
Upon analysis of nasal swab samples, the research demonstrated an immediate and highly significant (99.9+% ~3 log10) reduction in viable bacterial cells and number of species, sustained for at least 24 hours. Importantly, within a week, the microbiome rebounded to its original diversity and quantity. These findings support Steriwave as an efficient, potent, short-acting, and non-selective method of nasal decolonization, with the advantage of rapid recovery of the native microbiome post-treatment.
In comparison to antibiotics, the study demonstrated that Steriwave is far less likely to significantly alter the native microbiota. The antibiotic mupirocin, commonly used for nasal decolonization, has been shown to affect microbiota diversity for over 6 months, allowing disease-causing pathogens like Staphylococcus aureus to colonize the nose before beneficial species, putting patients at increased risk of infection.[1] Steriwave, in contrast, offers a more favourable profile with the study results showing a reduced risk of long-term microbiome disruption, as the microbiome consistently returns to baseline.
Notably, minimizing microbiome disruption is also important in safeguarding immune function, reducing vulnerability to infectious diseases by maintenance of a microecological environment populated by beneficial commensal microbes instead of disease-causing species.[2] The oral research presentation, delivered by Ondine's Director of Research and Development, Dr. Caetano Sabino, reported results from an exploratory study involving 35 healthy volunteers, examining the responses of the nasal microbial population after Steriwave treatment.
Ondine Biomedical Inc. is a Canadian life science company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave®. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) will present new research at the SPIE Photonics West conference in San Francisco, California. The presentation will provide details of an exploratory study showing that photodisinfection significantly reduces pathogens in the nose - a reservoir for bacteria - yet does not produce long-term adverse effects on the nasal microbiome.1 Organised by SPIE, the international society for optics and photonics, SPIE Photonics West is the largest annual event for optic and photonic technologies and one of the largest scientific conferences in the world.
These results demonstrate that Steriwave is an effective, potent, short-acting, and non-selective method of nasal decolonization, while permitting rapid recovery of the native microbiome at one week after treatment. The study involved analyzing nasal swabs from 35 healthy volunteers after being treated with Ondine's Steriwave® Nasal Photodisinfection System.
The oral presentation will be delivered by Ondine's Director of Research and Development, Dr Caetano Sabino, at 9am on Tuesday, 30 January 2024, as part of the "Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases" session.
The "Microbiome Analysis of Photodynamic Nasal Decolonization" abstract can be accessed here.